ANON
MCID: ANR007
MIFTS: 68

Anorexia Nervosa (ANON)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Anorexia Nervosa

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 58 12 77 76 56 45 15 17 74
Anorexia Nervosa, Susceptibility to, 1 58 13 41
Anorexia Nervosa, Susceptibility to 58 13
Anorexia Nervosa 1 58 30
Anon 58 76
an 58

Classifications:



External Ids:

Disease Ontology 12 DOID:8689
OMIM 58 606788
ICD9CM 36 307.1
MeSH 45 D000856
NCIt 51 C34387
SNOMED-CT 69 56882008
ICD10 34 F50.0 F50.00
MedGen 43 C1853221
UMLS 74 C0003125

Summaries for Anorexia Nervosa

OMIM : 58 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788)

MalaCards based summary : Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, 1, is related to acanthosis nigricans and eating disorder, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Dopamine and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

UniProtKB/Swiss-Prot : 76 Anorexia nervosa: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea.

Wikipedia : 77 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder, characterized by low... more...

Related Diseases for Anorexia Nervosa

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 11082)
# Related Disease Score Top Affiliating Genes
1 acanthosis nigricans 33.0 ADIPOQ IGF1 LEP PRL
2 eating disorder 32.2 ADIPOQ BDNF CCK CRH GHRL LEP
3 bulimia nervosa 31.7 BDNF CCK GHRL HTR2A LEP NPY
4 adenoma 31.7 GH1 IGF1 POMC PRL
5 traumatic brain injury 31.7 BDNF GH1 IGF1
6 depression 31.5 BDNF CRH HTR2A SLC6A4
7 allergic encephalomyelitis 31.5 CRH POMC
8 dyspepsia 31.4 CCK GHRL SLC6A4
9 anxiety 31.4 BDNF CRH HTR2A NPY SLC6A4
10 amenorrhea 31.4 CRH LEP POMC PRL
11 mccune-albright syndrome 31.4 GH1 IGF1 PRL
12 laron syndrome 31.3 GH1 GHR IGF1
13 fatty liver disease, nonalcoholic 1 31.3 ADIPOQ LEP RETN
14 personality disorder 31.3 BDNF HTR2A PRL SLC6A4
15 empty sella syndrome 31.3 GH1 IGF1 POMC PRL
16 fibrous dysplasia 31.3 GH1 IGF1 PRL
17 sleep apnea 31.2 ADIPOQ GHRL HTR2A IGF1 LEP LEPR
18 anovulation 31.2 IGF1 LEP PRL
19 polycystic ovary syndrome 31.2 IGF1 LEP PRL
20 coronary artery aneurysm 31.2 ADIPOQ LEP RETN
21 intermittent explosive disorder 31.2 NPY PRL SLC6A4
22 retrograde amnesia 31.2 POMC SLC6A4
23 psychotic disorder 31.1 BDNF HTR2A PRL SLC6A4
24 obsessive-compulsive disorder 31.1 BDNF CRH HTR2A PRL SLC6A4
25 3-hydroxyacyl-coa dehydrogenase deficiency 31.1 ADIPOQ GHRL LEP RETN
26 lipid metabolism disorder 31.1 ADIPOQ LEP RETN
27 gestational diabetes 31.1 ADIPOQ LEP RETN
28 substance dependence 31.1 BDNF POMC SLC6A4
29 hyperprolactinemia 31.1 GH1 IGF1 POMC PRL
30 atypical depressive disorder 31.1 CRH HTR2A SLC6A4
31 attention deficit-hyperactivity disorder 31.1 BDNF HTR2A NPY SLC6A4
32 borderline personality disorder 31.1 BDNF HTR2A SLC6A4
33 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 31.0 LEP POMC
34 postpartum depression 31.0 BDNF CRH PRL SLC6A4
35 chiasmal syndrome 31.0 POMC PRL
36 pseudohypoparathyroidism, type ia 31.0 GH1 IGF1 PRL
37 uremia 31.0 GHR LEP RETN
38 pituitary tumors 31.0 GH1 IGF1 POMC PRL
39 pancreas disease 30.9 CCK IGF1 LEP POMC
40 fibromyalgia 30.9 CRH HTR2A IGF1 NPY PRL SLC6A4
41 hyperinsulinism 30.9 GH1 GHRL IGF1 LEP
42 gigantism 30.9 GH1 GHRH PRL
43 isolated growth hormone deficiency, type ii 30.9 GH1 GHR GHRH IGF1
44 glucose intolerance 30.9 ADIPOQ GHRL IGF1 LEP LEPR RETN
45 hyperthyroidism 30.8 GH1 GHRL LEP PRL
46 conn's syndrome 30.7 CRH GH1 POMC PRL
47 nutritional deficiency disease 30.7 GHRL IGF1 LEP
48 schizophrenia 30.7 BDNF CCK HTR2A NPY PRL SLC6A4
49 craniopharyngioma 30.6 GH1 GHRL IGF1 PRL
50 generalized anxiety disorder 30.6 BDNF HTR2A SLC6A4

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa

Symptoms & Phenotypes for Anorexia Nervosa

Clinical features from OMIM:

606788

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ADIPOQ AGRP BDNF CCK CRH GHR
2 behavior/neurological MP:0005386 10.36 ADIPOQ AGRP BDNF CRH GHR GHRL
3 endocrine/exocrine gland MP:0005379 10.34 ADIPOQ BDNF CCK CRH GHR GHRH
4 adipose tissue MP:0005375 10.3 ADIPOQ AGRP CRH GHR GHRL IGF1
5 growth/size/body region MP:0005378 10.29 ADIPOQ AGRP BDNF CRH GHR GHRH
6 liver/biliary system MP:0005370 10.14 ADIPOQ AGRP CRH GHR GHRH LEP
7 integument MP:0010771 10.13 ADIPOQ BDNF CRH GHR IGF1 LEP
8 nervous system MP:0003631 10.13 ADIPOQ AGRP BDNF CCK CRH GHR
9 muscle MP:0005369 9.91 ADIPOQ GHR HTR2A IGF1 LEP LEPR
10 normal MP:0002873 9.81 AGRP BDNF CRH GHRL IGF1 LEPR
11 neoplasm MP:0002006 9.8 ADIPOQ IGF1 LEP LEPR POMC PRL
12 renal/urinary system MP:0005367 9.61 ADIPOQ CCK CRH GHR IGF1 LEP
13 skeleton MP:0005390 9.28 ADIPOQ CRH GHR HTR2A IGF1 LEP

Drugs & Therapeutics for Anorexia Nervosa

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Not Applicable 62-31-7, 51-61-6 681
2
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
3
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
4
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Hydroxyzine Approved Phase 4 68-88-2 3658
8
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 3007 5826
9
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
10 Raclopride Investigational Phase 4 84225-95-6
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Dopamine Antagonists Phase 4,Phase 3
20 Serotonin Antagonists Phase 4,Phase 3
21 Dopamine Agents Phase 4,Phase 3
22 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
23 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Not Applicable
26 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3
27 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3
28 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2,Not Applicable
29 Dopamine agonists Phase 4,Phase 3,Not Applicable
30 Dopamine D2 Receptor Antagonists Phase 4,Phase 3
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
35
Histamine Phosphate Phase 4 51-74-1 65513
36 Histamine H1 Antagonists Phase 4
37 Histamine Antagonists Phase 4
38 Antipruritics Phase 4
39 Dermatologic Agents Phase 4
40 Adrenergic Agents Phase 4,Not Applicable
41 Dopamine Uptake Inhibitors Phase 4
42 Central Nervous System Stimulants Phase 4
43 Sympathomimetics Phase 4,Not Applicable
44
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
45
Teriparatide Approved, Investigational Phase 3,Phase 2 52232-67-4 16133850
46
Mecasermin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68562-41-4
47
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
48
Progesterone Approved, Vet_approved Phase 3,Phase 2 57-83-0 5994
49
tannic acid Approved Phase 3 1401-55-4
50
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1 28014-46-2

Interventional clinical trials:

(show top 50) (show all 248)
# Name Status NCT ID Phase Drugs
1 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
4 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
5 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
6 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
8 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
11 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
12 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
13 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
14 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Terminated NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
15 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
16 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
17 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
18 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
19 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
20 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
21 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
22 Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Unknown status NCT01761942 Phase 2
23 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Unknown status NCT01611220 Phase 2
24 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
25 Transdermal Estrogen in Women With Anorexia Nervosa Not yet recruiting NCT03875378 Phase 2 Transdermal estrogen;Placebos
26 Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
27 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
28 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
29 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
30 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Completed NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
31 Estrogen Replacement in Anorexia Nervosa Terminated NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
32 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
33 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2 Olanzapine
34 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
35 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
36 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
37 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
38 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
39 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
40 The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
41 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
42 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
43 The Role of Estrogen in the Neurobiology of Eating Disorders Recruiting NCT03740204 Phase 2 17-β estradiol transdermal patches with cyclic progesterone;Placebo patch and pill
44 Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
45 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
46 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
47 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
48 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
49 Estradiol and Fear Extinction in Anorexia Nervosa (AN) Withdrawn NCT02792153 Phase 1 Estradiol
50 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Genetic Tests for Anorexia Nervosa

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa 1 30 HTR2A

Anatomical Context for Anorexia Nervosa

MalaCards organs/tissues related to Anorexia Nervosa:

42
Bone, Brain, Heart, Breast, Kidney, Skin, Lung

Publications for Anorexia Nervosa

Articles related to Anorexia Nervosa:

(show top 50) (show all 3820)
# Title Authors Year
1
Factorial Validity of the Toronto Alexithymia Scale (TAS-20) in Clinical Samples: A Critical Examination of the Literature and a Psychometric Study in Anorexia Nervosa. ( 29603033 )
2019
2
A loss of consciousness in a teenage girl with anorexia nervosa, due to polydipsia: case report and a minireview. ( 30712218 )
2019
3
"Do I exist in this world, really, or is it just her?" Youths' perspectives of living with a sibling with anorexia nervosa. ( 30712482 )
2019
4
A Longitudinal Study of Eating Rituals in Patients With Anorexia Nervosa. ( 30713513 )
2019
5
Reciprocal relations between dietary restraint and negative affect in adolescents receiving treatment for anorexia nervosa. ( 30714794 )
2019
6
Long-term follow-up study of low-weight avoidant restrictive food intake disorder compared with childhood-onset anorexia nervosa: Psychiatric and occupational outcome in 56 patients. ( 30741442 )
2019
7
Histone deacetylase 4 (HDAC4): a new player in anorexia nervosa? ( 30742020 )
2019
8
Eyelid petechiae as a window to relapse in a case of purging-type anorexia nervosa. ( 30745664 )
2019
9
Medical Assessment and Triage of Pediatric Patients with Anorexia Nervosa in Primary Care. ( 30747833 )
2019
10
Anorexia nervosa presenting as diffuse spontaneous air leaks. ( 30755429 )
2019
11
Predictors of early response in conjoint and separated models of family-based treatment for adolescent anorexia nervosa. ( 30761665 )
2019
12
To glance on psychiatric comorbidity in adolescent with anorexia nervosa. ( 30761816 )
2019
13
Long-term outcome and psychiatric comorbidity of adolescent-onset anorexia nervosa. ( 30764636 )
2019
14
Anorexia nervosa requiring admission in adolescents. ( 30765357 )
2019
15
Abnormal Spontaneous Regional Brain Activity in Young Patients With Anorexia Nervosa. ( 30768380 )
2019
16
Comparisons of bone density and body composition among adolescents with anorexia nervosa and atypical anorexia nervosa. ( 30771231 )
2019
17
Long-term Outcomes of Adolescent Anorexia Nervosa on Bone. ( 30819332 )
2019
18
Visual scanning during emotion recognition in long-term recovered anorexia nervosa: An eye-tracking study. ( 30828832 )
2019
19
Decline of Plasma Concentrations of Interleukin-18 in Severely Malnourished Patients with Anorexia Nervosa: Exploratory Analysis. ( 30832404 )
2019
20
Cortical thickness 20 years after diagnosis of anorexia nervosa during adolescence. ( 30847623 )
2019
21
White matter alterations in anorexia nervosa: evidence from a voxel-based meta-analysis. ( 30851283 )
2019
22
Suboptimal bone microarchitecure in adolescent girls with obesity compared to normal-weight controls and girls with anorexia nervosa. ( 30853658 )
2019
23
Set-shifting in adolescents with weight-restored anorexia nervosa and their unaffected family members. ( 30856379 )
2019
24
Reducing anorexia nervosa stigma: an exploration of a social consensus intervention and the moderating effect of blameworthy attributions. ( 30862256 )
2019
25
Microduplications at the 15q11.2 BP1-BP2 locus are enriched in patients with anorexia nervosa. ( 30878790 )
2019
26
The effect of intranasal oxytocin on the perception of affective touch and multisensory integration in anorexia nervosa: protocol for a double-blind placebo-controlled crossover study. ( 30878983 )
2019
27
Is there a link between stress and immune biomarkers and salivary opiorphin in patients with a restrictive-type of anorexia nervosa? ( 30880537 )
2019
28
An update on the medical consequences of anorexia nervosa. ( 30883398 )
2019
29
Anorexia Nervosa and a Lost Emotional Self: A Psychological Formulation of the Development, Maintenance, and Treatment of Anorexia Nervosa. ( 30886593 )
2019
30
Predicting the restrictive eating, exercise, and weight monitoring compulsions of anorexia nervosa. ( 30900140 )
2019
31
Same, same but different: Attention bias for food cues in adults and adolescents with anorexia nervosa. ( 30912189 )
2019
32
Increased lipid and lipoprotein concentrations in anorexia nervosa: A systematic review and meta-analysis. ( 30920679 )
2019
33
Oral contraceptives partially protect from bone loss in young women with anorexia nervosa. ( 30922647 )
2019
34
Dynamics of nurses' authority in the inpatient care of adolescent consumers with anorexia nervosa: A qualitative study of nursing perspectives. ( 30931550 )
2019
35
Body parts of clinical concern in anorexia nervosa versus body dysmorphic disorder: a cross-diagnostic comparison. ( 30931578 )
2019
36
Anorexia nervosa is associated with Neuronatin variants. ( 30933048 )
2019
37
Task-sharing interventions for patients with anorexia nervosa or their carers: a systematic evaluation of the literature and meta-analysis of outcomes. ( 30950660 )
2019
38
Anorexia nervosa: Gut microbiota-immune-brain interactions. ( 30952533 )
2019
39
Micronutrients Deficiencies in 374 Severely Malnourished Anorexia Nervosa Inpatients. ( 30959831 )
2019
40
Early changes in depression predict outcomes of inpatient adolescent anorexia nervosa. ( 30963421 )
2019
41
Associations between interoceptive sensitivity, intuitive eating, and body mass index in patients with anorexia nervosa and normal-weight controls. ( 30968474 )
2019
42
In pursuit of middle ground: understanding the bone benefits of hormonal contraception in women with anorexia nervosa. ( 30975385 )
2019
43
Comparison of body image evaluation by virtual reality and paper-based figure rating scales in adolescents with anorexia nervosa: retrospective study. ( 30977098 )
2019
44
Sample size in clinical trials on anorexia nervosa: a rejoinder to Jenkins. ( 30977459 )
2019
45
Motivation to eat and not to eat - The psycho-biological conflict in anorexia nervosa. ( 30980856 )
2019
46
Adipokines, cortisol and cytokine alterations in recent onset anorexia nervosa. A case-control study. ( 30981680 )
2019
47
Fat preference and fat intake in individuals with and without anorexia nervosa. ( 30981752 )
2019
48
Long-term Skeletal Consequences of Anorexia Nervosa: A "Wake up Call". ( 30819327 )
2019
49
Bone mineral density and estimated hip strength in men with anorexia nervosa, atypical anorexia nervosa and avoidant/restrictive food intake disorder. ( 30817009 )
2019
50
Gender Dysphoria and Anorexia Nervosa Symptoms in Two Adolescents. ( 30815831 )
2019

Variations for Anorexia Nervosa

Expression for Anorexia Nervosa

Search GEO for disease gene expression data for Anorexia Nervosa.

Pathways for Anorexia Nervosa

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 CCK CRH GH1 GHR GHRH GHRL
2
Show member pathways
12.84 BDNF CRH GH1 GHRH HTR2A POMC
3
Show member pathways
12.29 GH1 LEP LEPR PRL
4
Show member pathways
12.24 ADIPOQ IGF1 LEP LEPR
5
Show member pathways
12.17 GH1 GHR LEP LEPR PRL
7
Show member pathways
11.98 GH1 GHRL IGF1 LEP POMC
8 11.78 ADIPOQ GH1 IGF1 LEP RETN
9 11.54 BDNF GH1 GHRH IGF1
10 11.5 GH1 GHR IGF1
11 11.33 LEP LEPR PRL
12
Show member pathways
11.22 GH1 GHR PRL
13
Show member pathways
11.02 LEP LEPR POMC
14 10.94 ADIPOQ AGRP LEP LEPR NPY POMC
15 10.79 AGRP POMC
16 10.32 CRH POMC

GO Terms for Anorexia Nervosa

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 ADIPOQ AGRP BDNF CCK CRH GH1
2 neuronal cell body GO:0043025 9.65 AGRP CCK CRH GHR HTR2A
3 extracellular space GO:0005615 9.53 ADIPOQ AGRP BDNF CCK CRH GH1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 9.16 GH1 GHR

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 CCK CRH GHRH HTR2A IGF1 LEP
2 response to drug GO:0042493 9.93 ADIPOQ CRH HTR2A SLC6A4
3 glucose homeostasis GO:0042593 9.91 ADIPOQ LEP LEPR POMC
4 female pregnancy GO:0007565 9.89 CRH LEP PRL
5 neuropeptide signaling pathway GO:0007218 9.88 AGRP NPY POMC PYY
6 response to insulin GO:0032868 9.87 AGRP LEP RETN
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 GH1 IGF1 LEP
8 regulation of blood pressure GO:0008217 9.86 LEP NPY POMC
9 glucose metabolic process GO:0006006 9.85 ADIPOQ GHRL LEP
10 response to hypoxia GO:0001666 9.84 ADIPOQ LEP SLC6A4
11 positive regulation of cold-induced thermogenesis GO:0120162 9.84 ADIPOQ GHRL LEP LEPR
12 hormone-mediated signaling pathway GO:0009755 9.83 AGRP GHR GHRL
13 memory GO:0007613 9.81 BDNF CCK HTR2A SLC6A4
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 GH1 GHR IGF1 LEP
15 feeding behavior GO:0007631 9.79 AGRP NPY PYY
16 response to ethanol GO:0045471 9.79 ADIPOQ CRH LEP
17 regulation of multicellular organism growth GO:0040014 9.77 GHR IGF1 PRL
18 response to estradiol GO:0032355 9.76 GH1 LEP SLC6A4
19 energy reserve metabolic process GO:0006112 9.72 LEP LEPR
20 hormone metabolic process GO:0042445 9.72 GHR LEP
21 negative regulation of gluconeogenesis GO:0045721 9.72 ADIPOQ LEPR
22 eating behavior GO:0042755 9.72 AGRP CCK LEP
23 central nervous system neuron development GO:0021954 9.71 LEP NPY
24 insulin-like growth factor receptor signaling pathway GO:0048009 9.71 GHR IGF1
25 growth hormone receptor signaling pathway GO:0060396 9.71 GH1 GHR
26 positive regulation of growth GO:0045927 9.71 GH1 GHRL
27 regulation of feeding behavior GO:0060259 9.71 AGRP LEPR
28 positive regulation of multicellular organism growth GO:0040018 9.71 GH1 GHR GHRH GHRL
29 sexual reproduction GO:0019953 9.7 LEP LEPR
30 response to nutrient GO:0007584 9.7 ADIPOQ LEP SLC6A4
31 leptin-mediated signaling pathway GO:0033210 9.69 LEP LEPR
32 negative regulation of appetite GO:0032099 9.69 CCK LEP
33 positive regulation of growth hormone secretion GO:0060124 9.68 GHRH GHRL
34 growth hormone secretion GO:0030252 9.68 GHRH GHRL
35 positive regulation of feeding behavior GO:2000253 9.67 AGRP GHRL
36 positive regulation of behavioral fear response GO:2000987 9.67 CCK CRH
37 regulation of bone remodeling GO:0046850 9.67 LEP LEPR
38 circadian rhythm GO:0007623 9.67 ADIPOQ AGRP LEP SLC6A4
39 bone mineralization involved in bone maturation GO:0035630 9.65 IGF1 LEP
40 negative regulation of glucagon secretion GO:0070093 9.65 CRH LEP
41 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.65 GH1 GHR PRL
42 response to nutrient levels GO:0031667 9.65 ADIPOQ GH1 GHRL LEP PRL
43 positive regulation of corticotropin secretion GO:0051461 9.64 CRH GHRL
44 positive regulation of cortisol secretion GO:0051464 9.64 CRH GHRL
45 positive regulation of appetite GO:0032100 9.63 GHRL NPY
46 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.63 GH1 GHRH IGF1
47 positive regulation of JAK-STAT cascade GO:0046427 9.62 GH1 GHR LEP PRL
48 bone growth GO:0098868 9.57 LEP LEPR
49 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.56 CRH GHRL
50 regulation of signaling receptor activity GO:0010469 9.47 ADIPOQ AGRP BDNF CCK GH1 GHRH

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.8 ADIPOQ AGRP CRH LEP NPY POMC
2 G protein-coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
3 serotonin binding GO:0051378 9.43 HTR2A SLC6A4
4 neuropeptide hormone activity GO:0005184 9.43 AGRP CCK CRH GHRH NPY PYY
5 growth hormone-releasing hormone activity GO:0016608 9.4 GHRH GHRL
6 hormone activity GO:0005179 9.4 ADIPOQ CCK CRH GH1 GHRL IGF1
7 prolactin receptor binding GO:0005148 9.37 GH1 PRL
8 peptide hormone receptor binding GO:0051428 9.33 CCK GHRH LEP

Sources for Anorexia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....